Home » Sports » Sharapova drugs ban reduced on appeal

Sharapova drugs ban reduced on appeal

Maria Sharapova’s two-year doping ban has been reduced to 15 months following her appeal to the Court of Arbitration for Sport.

The five-time Grand Slam winner, 29, was initially banned by the International Tennis Federation for two years after testing positive for meldonium at the 2016 Australian Open.

The Russian will be able to return to the tennis court on 26 April, 2017.

“I am counting the days until I can return,” she said.

“In so many ways, I feel like something I love was taken away from me and it will feel really good to have it back. Tennis is my passion and I have missed it.”

  • Reaction to Sharapova’s reduced ban
  • What is meldonium?
  • Watch: How to avoid failing a drugs test

Meldonium, a heart disease drug also known as mildronate, became a banned substance on 1 January 2016.

Sharapova said she had been taking the drug since 2006 for health problems and had “not tried to use a performance-enhancing substance”.

She said she was unaware the drug had been added to the World Anti-Doping Agency’s (Wada) banned list.

The former world number one said she could not “accept” the “unfairly harsh” ban when it was announced in June.

The Cas panel said it found Sharapova’s case “was not about an athlete who cheated”.

It added that Sharapova was at fault for not giving her agent “adequate instructions” in checking Wada’s prohibited list and “failing to supervise and control” her agent.

The tribunal ruling said Sharapova tested positive for meldonium after her Australian Open quarter-final defeat by Serena Williams on 26 January and in an out-of-competition test on 2 February.

Cas treated both results as a single anti-doping violation.

‘One of my happiest days’

Sharapova won the Wimbledon singles title as a 17-year-old in 2004, going on to win the Australian, French and US Opens to complete a career Grand Slam.

However, she has not played professional tennis since losing to 22-time Grand Slam champion Williams.

“I’ve gone from one of the toughest days of my career last March when I learned about my suspension to now, one of my happiest days, as I found out I can return to tennis in April,” she said.

“I have learned from this, and I hope the ITF has as well. Cas concluded that ‘the panel has determined it does not agree with many of the conclusions of the ITF tribunal’.

“I have taken responsibility from the very beginning for not knowing that the over-the-counter supplement I had been taking for the last 10 years was no longer allowed.

“But I also learned how much better other federations were at notifying their athletes of the rule change, especially in Eastern Europe where mildronate is commonly taken by millions of people.

“Now that this process is over, I hope the ITF and other relevant tennis anti-doping authorities will study what these other federations did, so that no other tennis player will have to go through what I went through.”

Why the appeal has been reduced – the key findings

Sharapova appealed against the original two-year ban on the grounds there was “no significant fault or negligence” on her part.

The Cas panel accepted her claim of no significant fault, saying she had a reduced perception of the risk she was incurring by taking mildronate.

That was because:

  • She had used mildronate for 10 years without any anti-doping issue
  • She did not seek treatment from her doctor, Anatoly Skalny, to obtain a performance-enhancing product, but used it only for medical reasons
  • No specific warning had been issued by Wada, the ITF or the WTA about a change in the status of meldonium
  • She took a public position acknowledging that she took meldonium and accepted responsibility

Cas said the sanction should be reduced to 15 months “based on its analysis of Sharapova’s degree of fault”.

It said Sharapova “fell short” because:

  • She failed to monitor or supervise how her agent “met the anti-doping obligations imposed on an athlete”
  • She failed to discuss with her agent, Max Eisenbud, what needed to be done to check the continued availability of mildronate
  • She failed to put Eisenbud in contact with Dr Skalny to check if the product had not been added to Wada’s prohibited list

The panel added an athlete cannot “simply delegate her obligations to a third party and then not otherwise provide appropriate instructions, monitoring or supervision without bearing responsibility”.

Why can she return in April 2016?

Sharapova’s suspension is backdated to the date of her first positive test on 26 January 2016, meaning she can return to competitive action before the French Open in May 2017.

But with her world ranking dropping to 95 since her last appearance – and going to fall further – she will need to be awarded a wildcard to play at Roland Garros.

The WTA’s protected ranking rules only allows players who are sidelined with a long-term injury to return to competition to use their ranking at the time of the start of their absence.

Sponsor ‘proud to have stood by Sharapova’

Racquet manufacturer Head, which extended its contract with Sharapova despite her positive test, congratulated her after the ban was reduced.

Nike suspended its relationship with Sharapova in March, before saying it would stand by her following the tribunal’s findings in June.

Car manufacturer Porsche said it would wait to see the outcome of her appeal, while Swiss watchmaker Tag Heuer cut ties with her in March.

Sharapova was Forbes’ highest-paid female athlete for 11 consecutive years, until Williams moved above her this year.

The latest Forbes figures have Sharapova’s winnings and endorsements at £17.1m, compared with £22.6m for Williams.

Source: BBC

Leave a Reply

Your email address will not be published. Required fields are marked *



Check Also


Valerenga And Brøndby Agree On Adam Kwarasey Transfer

Vålerenga and Brøndby have today agreed on a transfer of Adam Larsen Kwarasay Citisports can ...